Vittorio Montefusco

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 60 publications

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Journal: Clinical lymphoma, myeloma & leukemia
Published: April 27, 2026

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study.

Journal: Cancer
Published: February 19, 2026

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Journal: European journal of haematology
Published: September 27, 2025

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape.

Journal: ESMO open
Published: July 11, 2025

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

Journal: BMC cancer
Published: April 17, 2025

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials.

Journal: Haematologica
Published: September 15, 2024

Use of Software as a Medical Device to Improve Therapeutic Adherence in Patients With Hematological Malignancies: Prospective Interventional MargheRITA Study.

Use of Software as a Medical Device to Improve Therapeutic Adherence in Patients With Hematological Malignancies: Prospective Interventional MargheRITA Study.

Journal: JMIR mHealth and uHealth
Published: April 18, 2024

Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review.

Use of immunoglobulin replacement therapy in patients with secondary antibody deficiency in daily practice: a European expert Q&A-based review.

Journal: Expert review of hematology
Published: April 03, 2023

Experts' consensus on the definition and management of high risk multiple myeloma.

Experts' consensus on the definition and management of high risk multiple myeloma.

Journal: Frontiers in oncology
Published: November 12, 2022

Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine.

Clinical, Morphological and Clonal Progression of VEXAS Syndrome in the Context of Myelodysplasia Treated with Azacytidine.

Journal: Clinical hematology international
Published: December 06, 2021

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.

Journal: Cancer
Published: November 05, 2020

Old and new generation proteasome inhibitors in multiple myeloma.

Old and new generation proteasome inhibitors in multiple myeloma.

Journal: Panminerva medica
Published: September 22, 2020
Showing 1-12 of 60

Last Updated: 09/26/2026